Merck's Novel Antibiotic For Abdominal, Urinary Tract Infections Receives FDA Nod
Merck's Novel Antibiotic For Abdominal, Urinary Tract Infections Receives FDA Nod. Merck & Co., Inc. (NYSE: MRK) continues to find success with its product pipeline, with another of its treatment options receiving FDA approval. The drug is intended to treat patients 18 and older for complicated urinary tract infection, or cUTI — including pyelonephritis — caused by some susceptible gram-negative microorganisms and for which there is limited or no alternative treatment options. "RECARBRIO offers an additional treatment option for patients with cIAI and cUTI who have limited and, in some cases, no alternative therapeutic options," Keith Kaye, a principal investigator of the clinical program that evaluated the antibiotic combo, said in a statement.